Elekta AB (EKTAY)
7.365
+0.21
(+2.94%)
USD |
OTCM |
May 10, 15:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.814B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.70% |
| Valuation | |
| PE Ratio | 20.74 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.636 |
| Price to Book Value | 2.858 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1157 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5719 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 67.83% |
Profile
| Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,000 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 31%; Europe, the Middle East, and Africa accounting for 35%; and the Asia-Pacific contributing the remainder. |
| URL | https://www.elekta.com |
| Investor Relations URL | https://www.elekta.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Jun. 05, 2024 |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 26, 2024 |
Ratings
Profile
| Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,000 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 31%; Europe, the Middle East, and Africa accounting for 35%; and the Asia-Pacific contributing the remainder. |
| URL | https://www.elekta.com |
| Investor Relations URL | https://www.elekta.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Jun. 05, 2024 |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 26, 2024 |